UPDATE ON THE STANLEY
FOUNDATION SCHIZOPHRENIA TREATMENT NETWORK
Michael B. Knable
Stanley Foundation, Bethesda, MD
Despite many new advances in the
psychopharmacology of schizophrenia, the majority of patients
suffer from residual symptoms even with optimal treatment. In
order to stimulate novel approaches to the management of these
symptoms, the Stanley Foundation is organizing a multi-site,
collaborative investigation of new treatments. The current goals
and structure of the network will be described. Potential
candidate drugs for study will also be presented.